Revolution Medicines (RVMD) Total Current Liabilities (2019 - 2026)

Revolution Medicines' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $289.6 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 82.6% year-over-year to $289.6 million; the TTM figure through Mar 2026 stood at $289.6 million (up 82.6% YoY), while the FY2025 annual figure was $290.4 million, up 77.18% from the prior year.
• Total Current Liabilities was $289.6 million for Q1 2026 at Revolution Medicines, roughly flat from $290.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $290.4 million in Q4 2025 to a low of $54.6 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $133.0 million across 5 years, with a median of $105.3 million in 2024.
• Biggest YoY gain for Total Current Liabilities was 132.08% in 2023; the steepest drop was 4.91% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $62.0 million in 2022, then soared by 132.08% to $143.9 million in 2023, then advanced by 13.95% to $163.9 million in 2024, then jumped by 77.18% to $290.4 million in 2025, then dropped by 0.28% to $289.6 million in 2026.
• The last three Total Current Liabilities figures came in at $289.6 million (Q1 2026), $290.4 million (Q4 2025), and $245.6 million (Q3 2025), per Business Quant data.